Vikas Pilly, MD
Interventional Pain Medicine · Williamsville, NYNPI 1841302403
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,875 of the $19,136 with a category attached, or 77.7%. Caerus Corp. accounts for 77.7% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2020 at $15,008 and has fallen 97.7% since, to $348 in 2025.
Across 132 payments — averaging $144.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Caerus Corp.$15K
- Boston Scientific$1K
- Abbott$736
- Averitas Pharma Inc.$574
- Nevro Corp.$371
- Curonix LLC$365
- plus $982 from 19 others
What the payments were for
- Consulting fees$14,87578%
- Travel & lodging$2151%
- Food & beverage$4,04621%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Caerus Corp. | 1 | $14,875 |
| Boston Scientific | 25 | $1,233 |
| Abbott | 17 | $736 |
| Averitas Pharma Inc. | 21 | $574 |
| Nevro Corp. | 12 | $371 |
| Curonix LLC | 4 | $365 |
| Scilex Pharmaceuticals Inc. | 23 | $361 |
| International Rehabilitative Sciences, Inc | 2 | $180 |
| USWM, LLC | 4 | $77 |
| Collegium Pharmaceutical, Inc. | 3 | $55 |
| Vertex | 2 | $47 |
| Pfizer | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| AbbVie | 1 | $26 |
| Biodelivery Sciences International, Inc. | 2 | $26 |
| Medtronic | 1 | $18 |
| Saluda Medical Americas, Inc. | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Sentynl Therapeutics, Inc. | 1 | $17 |
| Zyla Life Sciences, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
| Shionogi Inc | 1 | $12 |
| UCB, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,136 in reported general payments places this provider in the 85th percentile of 132 interventional pain medicine providers in New York.
See all interventional pain medicine providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QutenzaCapsaicin/Skin Cleanser | 20 | $75,688 |
| Nucynta ErTapentadol Hcl | 13 | $8,060 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 101 | $4,439 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 153 | $3,782 |
| Gabapentin | 234 | $2,928 |
| Lidocaine | 12 | $2,081 |
| Naloxone Hcl | 27 | $1,955 |
| Tramadol Hcl ErTramadol Hcl | 11 | $1,795 |
| Pregabalin | 68 | $1,352 |
| Oxymorphone Hcl ErOxymorphone Hcl | 13 | $858 |
| Baclofen | 26 | $404 |
| Cyclobenzaprine Hcl | 33 | $362 |
| Tizanidine Hcl | 14 | $346 |
| Nortriptyline Hcl | 17 | $258 |
| Morphine Sulfate ErMorphine Sulfate | 11 | $240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta Er | $55 | $8,06013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 132 interventional pain medicine providers in New York.
Other interventional pain medicine in Williamsville
- Jafar SiddiquiWilliamsville$45K
- Corey HunterNew York$446K
- Neel MehtaNew York$432K
- Hemant KaliaRochester$179K
- Martin FerrilloAlbany$164K
- George ChaseKew Gardens$102K
- Kimberly SackheimNew York$102K
- Suelane OuroNew York$68K
- Gerard DegregorisNew York$49K
- Alexander WeingartenSyosset$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.